Solvay Analyzing “Various Options” For Its Pharma Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgian firm, which co-markets TriLipix and TriCor with Abbott, confirms it is in discussions with third-parties.
You may also be interested in...
Abbott's Solvay Pharma Buy More Salve Than Cure
Abbott Laboratories announced plans to acquire Solvay's pharmaceutical business for $6.6 billion Sept. 28, a strategic maneuver that seems as much about adding revenues to Abbott's top-line as addressing long-term challenges in the pharmaceutical pipeline
Abbott's Solvay Pharma Buy More Salve Than Cure
Abbott Laboratories announced plans to acquire Solvay's pharmaceutical business for $6.6 billion Sept. 28, a strategic maneuver that seems as much about adding revenues to Abbott's top-line as addressing long-term challenges in the pharmaceutical pipeline
Abbott Buys Solvay Pharma Unit But Is It Just A Short-Term Fix?
Abbott will buy the pharma business of its Belgian-based Tricor/TriLipix partner for $6.6 billion in cash; dependence on Humira, Tricor lingers.